KR20240052019A - 항-her2 항체 및 이의 사용 방법 - Google Patents

항-her2 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240052019A
KR20240052019A KR1020247009991A KR20247009991A KR20240052019A KR 20240052019 A KR20240052019 A KR 20240052019A KR 1020247009991 A KR1020247009991 A KR 1020247009991A KR 20247009991 A KR20247009991 A KR 20247009991A KR 20240052019 A KR20240052019 A KR 20240052019A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
heavy chain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247009991A
Other languages
English (en)
Korean (ko)
Inventor
아비라 반디오파디야이
알리사 제인 클레멘스
도진 김
미쉘 이. 피조
루 산
리차드 주니어 테올리스
레이몬드 카 항 통
Original Assignee
데날리 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데날리 테라퓨틱스 인크. filed Critical 데날리 테라퓨틱스 인크.
Publication of KR20240052019A publication Critical patent/KR20240052019A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247009991A 2021-08-25 2022-08-25 항-her2 항체 및 이의 사용 방법 Pending KR20240052019A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163237104P 2021-08-25 2021-08-25
US63/237,104 2021-08-25
PCT/US2022/075438 WO2023028543A2 (en) 2021-08-25 2022-08-25 Anti-her2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20240052019A true KR20240052019A (ko) 2024-04-22

Family

ID=85322213

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247009991A Pending KR20240052019A (ko) 2021-08-25 2022-08-25 항-her2 항체 및 이의 사용 방법

Country Status (12)

Country Link
US (2) US20250136713A1 (https=)
EP (1) EP4392458A4 (https=)
JP (1) JP2024534118A (https=)
KR (1) KR20240052019A (https=)
CN (1) CN117980342A (https=)
AR (1) AR126873A1 (https=)
AU (1) AU2022333088A1 (https=)
CA (1) CA3229542A1 (https=)
IL (1) IL311003A (https=)
MX (1) MX2024002406A (https=)
TW (1) TW202328186A (https=)
WO (1) WO2023028543A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2014357292B2 (en) * 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE

Also Published As

Publication number Publication date
EP4392458A2 (en) 2024-07-03
AR126873A1 (es) 2023-11-22
CN117980342A (zh) 2024-05-03
WO2023028543A3 (en) 2023-06-08
MX2024002406A (es) 2024-04-03
US20250136713A1 (en) 2025-05-01
IL311003A (en) 2024-04-01
CA3229542A1 (en) 2023-03-02
EP4392458A4 (en) 2025-11-19
WO2023028543A2 (en) 2023-03-02
AU2022333088A1 (en) 2024-03-07
US20260109781A1 (en) 2026-04-23
JP2024534118A (ja) 2024-09-18
TW202328186A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
JP7818042B2 (ja) 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
KR20260013489A (ko) TrkA 항체 및 이의 용도
KR20120014941A (ko) 인간 ｃｃｎ1에 대한 항체 및 이의 용도
CN113454120A (zh) 针对人免疫检查点CEACAM1（CD66a）的拮抗剂抗体及其制剂，试剂盒，和使用方法
TW202428608A (zh) 抗b7h3抗體以及其使用方法
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
HK40110414A (zh) 抗her2抗体及其使用方法
WO2024140925A1 (en) Anti-b7h3 antibodies and methods of use
KR20260027917A (ko) 이중 수송체 및 사용 방법
KR20250135302A (ko) 항-cmet 항체 및 사용 방법
HK40084724A (en) Engineered anti-her2 bispecific proteins
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000